{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029662","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.814673+00:00","generated_at":"2026-06-13T18:19:53.791599+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead","bullets":["Dr. Wayne Godfrey resigns as CMO effective July 5, 2023 for personal reasons; no disagreement with company.","Byron Robinson, Ph.D., Chief Strategy Officer, appointed interim head of clinical activities and team.","Robinson assumes leadership immediately; company emphasizes experienced clinical team remains in place."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029662","json":"https://secwatch.observer/filing/0000950170-23-029662.json","markdown":"https://secwatch.observer/filing/0000950170-23-029662.md","text":"https://secwatch.observer/filing/0000950170-23-029662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/janx-20230621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T18:19:53.791599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ecf84438a","claim":"Wayne Godfrey resigned as Chief Medical Officer at Janux Therapeutics, Inc..","evidence_excerpt":"On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"8dec5a7c3c","claim":"Byron Robinson was appointed as interim head of clinical activities at Janux Therapeutics, Inc..","evidence_excerpt":"On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"will take over"},{"label":"Role","value":"interim head of clinical activities"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}